Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 706, Issue 1-2, 2011, Pages 28-35

  Arafa, El Shaimaa A ^a   Zhu, Qianzheng ^a   Shah, Zubair I ^b   Wani, Gulzar ^a   Barakat, Bassant M ^a   Racoma, Ira ^a   El Mahdy, Mohamed A ^a   Wani, Altaf A ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Apoptosis; Breast cancer; Cell signaling; PTEN tumor suppressor; Thymoquinone

Indexed keywords

CASPASE; DOXORUBICIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; THYMOQUINONE;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LEVEL; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZOQUINONES; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASES; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; G2 PHASE; HUMANS; MOLECULAR STRUCTURE; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

NIGELLA SATIVA;

EID: 78650420222     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2010.10.007     Document Type: Article

References (51)

1. Hsu Y.L., Uen Y.H., Chen Y., Liang H.L., Kuo P.L. Tricetin, a dietary flavonoid, inhibits proliferation of human breast adenocarcinoma mcf-7 cells by blocking cell cycle progression and inducing apoptosis. J. Agric. Food Chem. 2009, 57:8688-8695.
2. Mellor H.R., Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 2008, 81:275-300.
3. Come S.E., Buzdar A.U., Ingle J.N., Johnston S.R., Brodie A.M., Coombes R.C., Miller W.R., Pritchard K.I., Winer E.P., Zujewski J.A., Goss P.E. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge conference. Cancer 2008, 112:673-678.
4. Rusetskaya N.V., Lukyanova N.Y., Chekhun V.F. Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin. Exp. Oncol. 2009, 31:140-143.
5. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev. 2008, 34:378-390.
6. Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998.
7. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995, 81:727-736.
8. Franke T.F., Cantley L.C. Apoptosis. A bad kinase makes good. Nature 1997, 390:116-117.
9. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 1998, 273:19929-19932.
10. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4240-4245.
11. Ren Y., Wu J. Simultaneous suppression of Erk and Akt/PKB activation by a Gab1 pleckstrin homology (PH) domain decoy. Anticancer Res. 2003, 23:3231-3236.
12. Hlobilkova A., Knillova J., Svachova M., Skypalova P., Krystof V., Kolar Z. Tumour suppressor PTEN regulates cell cycle and protein kinase B/Akt pathway in breast cancer cells. Anticancer Res. 2006, 26:1015-1022.
13. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 2001, 158:2097-2106.
14. Chung J.H., Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 2005, 65:8096-8100.
15. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin. Cell Dev. Biol. 2004, 15:171-176.
16. Freeman D.J., Li A.G., Wei G., Li H.H., Kertesz N., Lesche R., Whale A.D., Martinez-Diaz H., Rozengurt N., Cardiff R.D., Liu X., Wu H. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003, 3:117-130.
17. Tang Y., Eng C. PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res. 2006, 66:736-742.
18. Workman P., Clarke P.A., Raynaud F.I., van Montfort R.L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010, 70:2146-2157.
19. Sarkar F.H., Adsule S., Padhye S., Kulkarni S., Li Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini. Rev. Med. Chem. 2006, 6:401-407.
20. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65:6934-6942.
21. Arafa E.S., Zhu Q., Barakat B.M., Wani G., Zhao Q., El-Mahdy M.A., Wani A.A. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009.
22. Ali B.H., Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother. Res. 2003, 17:299-305.
23. Gali-Muhtasib H.U., bou Kheir W.G., Kheir L.A., Darwiche N., Crooks P.A. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs 2004, 15:389-399.
24. Al-Jenoobi F.I., Al-Thukair A.A., Abbas F.A., Ansari M.J., Alkharfy K.M., Al-Mohizea A.M., Al-Suwayeh S.A., Jamil S. Effect of black seed on dextromethorphan O- and N-demethylation in human liver microsomes and healthy human subjects. Drug Metab. Lett. 2010, 4:51-55.
25. Dehkordi F.R., Kamkhah A.F. Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fund. Clin. Pharmacol 2008, 22:447-452.
26. Shoieb A.M., Elgayyar M., Dudrick P.S., Bell J.L., Tithof P.K. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int. J. Oncol. 2003, 22:107-113.
27. Effenberger K., Breyer S., Schobert R. Terpene conjugates of the Nigella sativa seed-oil constituent thymoquinone with enhanced efficacy in cancer cells. Chem. Biodivers. 2010, 7:129-139.
28. Gurung R.L., Lim S.N., Khaw A.K., Soon J.F., Shenoy K., Mohamed A.S., Jayapal M., Sethu S., Baskar R., Hande M.P. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS ONE 2010, 5:e12124.
29. Trang N.T., Wanner M.J., Phuong L., Koomen V.G.J., Dung N.X. Thymoquinone from Eupatorium ayapana. Planta Med. 1993, 59:99.
30. Hosseinzadeh H., Parvardeh S. Anticonvulsant effects of thymoquinone, the major constituent of Nigella sativa seeds, in mice. Phytomedicine 2004, 11:56-64.
31. Gali-Muhtasib H., Roessner A., Schneider-Stock R. Thymoquinone: a promising anti-cancer drug from natural sources. Int. J. Biochem. Cell Biol. 2006, 38:1249-1253.
32. Ravindran J., Nair H.B., Sung B., Prasad S., Tekmal R.R., Aggarwal B.B. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem. Pharmacol. 2010, 79:1640-1647.
33. Effenberger-Neidnicht K., Schobert R. Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin. Cancer Chemother. Pharmacol. 2010.
34. Sethi G., Ahn K.S., Aggarwal B.B. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol. Cancer Res. 2008, 6:1059-1070.
35. Yi T., Cho S.G., Yi Z., Pang X., Rodriguez M., Wang Y., Sethi G., Aggarwal B.B., Liu M. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol. Cancer Ther. 2008, 7:1789-1796.
36. El-Mahdy M.A., Zhu Q., Wang Q.E., Wani G., Wani A.A. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int. J. Cancer 2005, 117:409-417.
37. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988, 48:4827-4833.
38. Lee E., Miyaguchi F., Inoue M., Kariya K., Sasaki H. A novel DNA cleaving agent, 2,2'-bis(2-aminoethyl)-4,4'-bithiazole, induces thymocyte apoptosis. Biochem. Mol. Biol. Int. 1996, 40:151-157.
39. El-Mahdy M.A., Zhu Q., Wang Q.E., Wani G., Praetorius-Ibba M., Wani A.A. Cullin 4A-mediated proteolysis of DDB2 protein at DNA damage sites regulates in vivo lesion recognition by XPC. J. Biol. Chem. 2006, 281:13404-13411.
40. Chekhun V.F., Lukyanova N.Y., Kovalchuk O., Tryndyak V.P., Pogribny I.P. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol. Cancer Ther. 2007, 6:1089-1098.
41. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., Pogribny I.P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 2008, 7:2152-2159.
42. Gali-Muhtasib H., ab-Assaf M., Boltze C., Al-Hmaira J., Hartig R., Roessner A., Schneider-Stock R. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int. J. Oncol. 2004, 25:857-866.
43. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
44. Yuan X.J., Whang Y.E. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002, 21:319-327.
45. Mayo L.D., Dixon J.E., Durden D.L., Tonks N.K., Donner D.B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 2002, 277:5484-5489.
46. Zhou M., Gu L., Findley H.W., Jiang R., Woods W.G. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 2003, 63:6357-6362.
47. Khader M., Bresgen N., Eckl P.M. In vitro toxicological properties of thymoquinone. Food Chem. Toxicol. 2009, 47:129-133.
48. Roepke M., Diestel A., Bajbouj K., Walluscheck D., Schonfeld P., Roessner A., Schneider-Stock R., Gali-Muhtasib H. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol. Ther. 2007, 6:160-169.
49. Porter L.A., Cukier I.H., Lee J.M. Nuclear localization of cyclin B1 regulates DNA damage-induced apoptosis. Blood 2003, 101:1928-1933.
50. Nicholson D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000, 407:810-816.
51. Paluszczak J., Krajka-Kuzniak V., Baer-Dubowska W. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol. Lett. 2010, 192:119-125.